Results 241 to 250 of about 791,464 (334)

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source

Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. [PDF]

J Eur Acad Dermatol Venereol, 2020
Papadavid E, Scaribrick J, Ortiz Romero P, Quaglino P, Vermeer M, Knobler R, Stadler R, Bagot M.   +7 more
europepmc   +1 more source

Aosta Valley animal cancer registry: A collaborative initiative for monitoring cancer burden in animals

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Animal cancer registry data are important for monitoring animal health, for prevention and research in veterinary medicine, and for comparative oncology. Since people and animals share the same environment and are exposed to many common risk factors, cancer patterns in animals may have a sentinel function for human health.
Claudio Trentin, Giulio Barigelletti, Caterina Abate, Giovanna Michela Villa, Emilio Bazzocchi, Lorenzo Domenis, Silvia Vuillermoz, Magda Giulia Santini, Barbara Avuzzi, Alessandro Borgini, Giovanna Tagliabue   +10 more
wiley   +1 more source

Cutaneous Lymphoma at Injection Sites

Veterinary Pathology-Supplement, 2016
P. Roccabianca, G. Avallone, A. Rodríguez, L. Crippa, E. Lepri, C. Giudice, M. Caniatti, P. Moore, V. Affolter   +8 more
semanticscholar   +1 more source

Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization [PDF]

, 1993
Cremer, Thomas, Knuutila, Sakari, Popp, Susanne, Ruutu, Tapani, Volin, L., Wessman, M.   +5 more
core  

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

International Journal of Cancer, Volume 158, Issue 10, Page 2581-2591, 15 May 2026.
What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser, Rasmus Mikiver, Karolin Isaksson, Mats Lambe, Gustav J. Ullenhag   +4 more
wiley   +1 more source

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. [PDF]

Cancers (Basel), 2020
Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM.   +5 more
europepmc   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

International Journal of Cancer, Volume 158, Issue 9, Page 2418-2428, 1 May 2026.
What's new? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin, Li Zhu, Yuyang Huang, Lizhu Chen, Yuping Lu, Yu Chen, Jing Lin   +6 more
wiley   +1 more source

Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. [PDF]

J Eur Acad Dermatol Venereol, 2020
Papadavid E, Scarisbrick J, Ortiz Romero P, Guaglino P, Vermeer M, Knobler R, Stadler R, Bagot M.   +7 more
europepmc   +1 more source